Please assess the completion status of the following clinical trial:

Trial Title: Bioenergetic Alterations After Exenatide Administration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* BMI between 30 and 40 kg/m2~* Women with a negative pregnancy test at baseline, who are sterile, using contraceptives or in a committed relationship with someone who is sterile or using contraception~* Absence of weight change greater than 3 kg in the previous 6 months~Exclusion Criteria:~* Women who are pregnant or lactating~* Current or recent (6 months) enrollment in a commercial or self prescribed weight loss or exercise program~* Use of weight loss medication~* A history of metabolic disease i.e. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study~* Presence of medical conditions that are known to affect energy expenditure (i.e. hyperthyroidism, rheumatoid arthritis, AIDS among others)~* History of hypoglycemia~* A history of psychiatric or eating disorder~* Abnormal EKG~* Previous history of pancreatitis~* Previous history of gastroparesis or GI motility disorder~* Use of medications that can affect GI motility~* History of organ transplantation~* Other comorbid conditions which may preclude the subject's ability to complete the study~* Use of a carbonic anhydrase inhibitor such as acetazolamide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).